| Imaging quality of <sup>44</sup>Sc in comparison with five other PET radionuclides using Derenzo phantoms and preclinical PET
Bunka, M., Müller, C., Vermeulen, C., Haller, S., Türler, A., Schibli, R., & van der Meulen, N. P. (2016). Imaging quality of 44Sc in comparison with five other PET radionuclides using Derenzo phantoms and preclinical PET. Applied Radiation and Isotopes, 110, 129-133. https://doi.org/10.1016/j.apradiso.2016.01.006 |
| Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of <sup>161</sup>Tb-folate and <sup>177</sup>Lu-folate
Haller, S., Pellegrini, G., Vermeulen, C., van der Meulen, N. P., Köster, U., Bernhardt, P., … Müller, C. (2016). Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of 161Tb-folate and 177Lu-folate. EJNMMI Research, 6(1), 13 (11 pp.). https://doi.org/10.1186/s13550-016-0171-1 |
| Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy
Haller, S., Reber, J., Brandt, S., Bernhardt, P., Groehn, V., Schibli, R., & Müller, C. (2015). Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy. Nuclear Medicine and Biology, 42(10), 770-779. https://doi.org/10.1016/j.nucmedbio.2015.06.006 |
| Investigation of the chick embryo as a potential alternative to the mouse for evaluation of radiopharmaceuticals
Haller, S., Ametamey, S. M., Schibli, R., & Müller, C. (2015). Investigation of the chick embryo as a potential alternative to the mouse for evaluation of radiopharmaceuticals. Nuclear Medicine and Biology, 42(3), 226-233. https://doi.org/10.1016/j.nucmedbio.2014.10.010 |
| Cyclotron production of <sup>44</sup>Sc: from bench to bedside
van der Meulen, N. P., Bunka, M., Domnanich, K., Müller, C., Haller, S., Vermeulen, C., … Schibli, R. (2015). Cyclotron production of 44Sc: from bench to bedside. Nuclear Medicine and Biology, 42(9), 745-751. https://doi.org/10.1016/j.nucmedbio.2015.05.005 |
| Direct in vitro and in vivo comparison of <sup>161</sup>Tb and <sup>177</sup>Lu using a tumour-targeting folate conjugate
Müller, C., Reber, J., Haller, S., Dorrer, H., Bernhardt, P., Zhernosekov, K., … Schibli, R. (2014). Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate. European Journal of Nuclear Medicine and Molecular Imaging, 41(3), 476-485. https://doi.org/10.1007/s00259-013-2563-z |
| Future prospects for SPECT imaging using the radiolanthanide terbium-155 — production and preclinical evaluation in tumor-bearing mice
Müller, C., Fischer, E., Behe, M., Köster, U., Dorrer, H., Reber, J., … Schibli, R. (2014). Future prospects for SPECT imaging using the radiolanthanide terbium-155 — production and preclinical evaluation in tumor-bearing mice. Nuclear Medicine and Biology, 41(S), e58-e65. https://doi.org/10.1016/j.nucmedbio.2013.11.002 |
| Improved PET imaging of tumors in mice using a novel <sup>18</sup>F-folate conjugate with an albumin-binding entity
Fischer, C. R., Groehn, V., Reber, J., Schibli, R., Ametamey, S. M., & Müller, C. (2013). Improved PET imaging of tumors in mice using a novel 18F-folate conjugate with an albumin-binding entity. Molecular Imaging and Biology, 15(6), 649-654. https://doi.org/10.1007/s11307-013-0651-x |
| DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted <sup>177</sup>Lu-radionuclide tumor therapy in mice
Müller, C., Struthers, H., Winiger, C., Zhernosekov, K., & Schibli, R. (2013). DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice. Journal of Nuclear Medicine, 54(1), 124-131. https://doi.org/10.2967/jnumed.112.107235 |
| PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with <sup>177</sup>Lu-DOTA-bombesin analogues
Däpp, S., Müller, C., Garayoa, E. G., Bläuenstein, P., Maes, V., Brans, L., … Schibli, R. (2012). PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues. EJNMMI Research, 2(1), 24 (12 pp.). https://doi.org/10.1186/2191-219X-2-24 |
| [<sup>18</sup>F]fluoro-deoxy-glucose folate: a novel PET radiotracer with improved in vivo properties for folate receptor targeting
Fischer, C. R., Müller, C., Reber, J., Müller, A., Krämer, S. D., Ametamey, S. M., & Schibli, R. (2012). [18F]fluoro-deoxy-glucose folate: a novel PET radiotracer with improved in vivo properties for folate receptor targeting. Bioconjugate Chemistry, 23(4), 805-813. https://doi.org/10.1021/bc200660z |
| 5-(2-<sup>18</sup>F-fluoroethoxy)-<sub>L</sub>-tryptophan as a substrate of system L transport for tumor imaging by PET
Krämer, S. D., Mu, L., Müller, A., Keller, C., Kuznetsova, O. F., Schweinsberg, C., … Ametamey, S. M. (2012). 5-(2-18F-fluoroethoxy)-L-tryptophan as a substrate of system L transport for tumor imaging by PET. Journal of Nuclear Medicine, 53(3), 434-442. https://doi.org/10.2967/jnumed.111.096289 |
| A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β<sup>−</sup>-radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative
Müller, C., Zhernosekov, K., Köster, U., Johnston, K., Dorrer, H., Hohn, A., … Schibli, R. (2012). A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β−-radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative. Journal of Nuclear Medicine, 53(12), 1951-1959. https://doi.org/10.2967/jnumed.112.107540 |
| Radioiodinated folic acid conjugates: evaluation of a valuable concept to improve tumor-to-background contrast
Reber, J., Struthers, H., Betzel, T., Hohn, A., Schibli, R., & Müller, C. (2012). Radioiodinated folic acid conjugates: evaluation of a valuable concept to improve tumor-to-background contrast. Molecular Pharmaceutics, 9(5), 1213-1221. https://doi.org/10.1021/mp200511t |
